ADAG Latest Press Releases

-- November 9, 2026 --

Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer Globe Newswire 7:00 AM

-- October 28, 2026 --

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer Globe Newswire 7:00 AM

-- October 27, 2026 --

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference Globe Newswire 7:00 AM

-- October 14, 2026 --

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference Globe Newswire 8:00 AM

-- September 22, 2026 --

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Globe Newswire 8:00 AM

-- September 10, 2026 --

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody Technology Globe Newswire 8:00 AM

-- September 9, 2026 --

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates Globe Newswire 8:00 AM

-- August 20, 2026 --

Adagene to Participate in Three Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 12, 2026 --

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes